COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0GW4K
|
|||
Drug Name |
Lopinavir + ritonavir + ribavirin + interferon beta-1b
|
|||
Synonyms |
Aluviran + norvir + rebetol + betaseron
|
|||
Drug Type |
Combination drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | COVID-19 3C-like protease (3CLpro) | Target Info | Inhibitor | [2] |
Lopinavir/ritonavir blocks viral replication of SARS-CoV-2 via inhibiting the 3C-like protease (3CLpro). | ||||
COVID-19 RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [3] | |
Ribavirin is a nucleoside against SARS-CoV-2. Its mechanism includes lethal mutagenesis of RNA virus genomes mediated by the SARS-CoV-2 RNA-dependent RNA polymerase. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04276688) Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | |||
2 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | |||
3 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.